You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search
Guidelines & Advice
About Guidelines Email Guidelines Team

PET Imaging in Brain Cancer

ID: PET 10 Jan 2009
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
N. Laperriere, C. Walker-Dilks, Ontario PET Steering Committee

Patient Population

Patients with gliomas.

Intended Guideline Users

To guide the Ontario PET Steering Committee in their decision making concerning indications for the use of PET imaging. This recommendation report may also be useful in informing clinical decision making regarding the appropriate role of PET imaging and in guiding priorities for future PET imaging research.

Research Question(s)

  1. What benefit to clinical management does positron emission tomography (PET) or positron emission tomography/computed tomography (PET/CT) contribute to the diagnosis or staging of gliomas?
  2. What benefit to clinical management does PET or PET/CT contribute to the assessment of treatment response for gliomas?
  3. What benefit to clinical management does PET or PET/CT contribute when recurrence of gliomas is suspected but not proven?
  4. What benefit to clinical management does PET or PET/CT contribute to restaging at the time of documented recurrence for gliomas?
  5. What is the role of PET when a solitary metastasis is identified at the time of recurrence and a metastectomy is being contemplated?
pdf download Summary (PDF) (166.06 KB)
pdf download Full Report (PDF) (273.43 KB)